A medical-isotope or radiopharmaceutical facility can look surprisingly small on a conventional land-use map. It may not have the smokestacks of a heavy industrial complex, the truck movements of a logistics hub or the footprint of a large hospital. Yet its operating geography can be exceptionally demanding because three clocks run at the same time.
The first is the radioactive-decay clock. Some medical radionuclides lose useful activity quickly, so production, testing, release, transport and clinical administration cannot be organised as if the product were an ordinary medicine sitting on a warehouse shelf. The second is the pharmaceutical-quality clock. A sterile radiopharmaceutical still has to meet the quality, aseptic-control and release requirements appropriate to a medicinal product. The third is the patient-care clock. A delayed batch is not merely delayed inventory; it can disrupt a diagnostic schedule or a treatment plan.
That combination turns town planning into a problem of proximity, resilience, regulated space and time.
This article owns the facility-scale reader job: how to plan a medical-isotope and radiopharmaceutical production campus as a land-use system. It does not replace nuclear regulation, radiation protection, pharmaceutical GMP, clinical nuclear medicine, emergency services, healthcare planning, transport-network owners, government owners or civilisation owners. It also does not replace TPW-0277, the Health-Care Waste Treatment Campus, or TPW-0236, the Biomanufacturing Campus Capacity Test. Its focus is the spatial system that must exist around medical-isotope production, radiochemistry, radiopharmacy, quality control, secure dispatch and decay-related logistics.
1. Start with the supply model, not the word “radiopharmaceutical”
There are several very different facility models hidden inside the same broad label.
One facility may receive radionuclides from elsewhere and prepare patient-ready products. Another may operate a cyclotron to produce short-lived radionuclides for local hospitals. Another may combine production, research, radiochemistry, aseptic filling and regional distribution. A larger campus may handle several product families, therapeutic isotopes, diagnostic products and development work.
Those models have different building, shielding, transport, waste, quality and staffing requirements.
The first planning document should therefore state what is produced on site, what arrives from external producers, what is formulated, what is distributed and what is used only for research.
2. The half-life creates geography
Ordinary manufacturing geography is often shaped by cost, labour, freight and market access.
Radiopharmaceutical geography can be shaped by time to a much greater degree.
Where useful activity declines rapidly, the distance between production and patient becomes part of the manufacturing system. A batch may need to move from accelerator or generator, through synthesis and quality checks, into controlled transport and then to a clinic on a schedule measured in hours rather than days.
That does not mean every hospital needs its own production facility. It means that planners should map the service radius and actual delivery-time reliability before choosing a site.
3. Regional supply can be more important than municipal boundaries
A radiopharmaceutical campus may serve several cities, hospitals and health systems.
The correct catchment may therefore be regional or national rather than local.
This matters because local planning decisions can affect healthcare resilience far beyond the host municipality. A road closure, airport disruption, flood or utility outage at one production site can interrupt supply across a large area.
The planning case should identify the normal service geography and the contingency geography.
4. A short-lived product changes the meaning of redundancy
A warehouse can often compensate for delayed manufacturing by carrying more stock.
That strategy is limited when the product itself decays.
Resilience may instead depend on additional production capacity, alternate suppliers, overlapping service areas, backup equipment, redundant utilities, validated contingency transport and carefully scheduled production.
The planner does not design the medical supply chain, but the site-selection process should ask whether the facility is a single point of failure for a critical region.
5. Distinguish accelerator production from pharmaceutical preparation
A cyclotron is not a radiopharmacy, and a radiopharmacy is not simply an accelerator support room.
The accelerator area, target systems, radiochemistry spaces, hot cells, clean or classified pharmaceutical areas, quality-control laboratories, decay storage, utility plant and dispatch functions can each have different controls.
A good planning submission makes these functions visible on a block plan.
That helps reviewers understand which parts are radiation-related, which are pharmaceutical-quality areas, which are ordinary support space and which create the external land-use interfaces.
6. Keep the radiation-safety boundary with the competent regulator
Town planners should not invent shielding thicknesses, activity limits or radiological operating procedures.
Those belong to the relevant nuclear, radiation-protection and occupational-safety authorities.
The planning job is to confirm that the design has a credible regulatory pathway, that controlled areas physically fit, that emergency access remains available and that surrounding land uses do not contradict the facility’s approved safety envelope.
This distinction protects both competence and accountability.
7. Keep pharmaceutical GMP as a separate regulatory layer
Radiopharmaceuticals intended for administration to patients are medicines.
That means product quality, aseptic processing where applicable, environmental control, investigations, equipment suitability, quality-unit oversight and release systems can become critical.
The FDA’s April 2026 warning letter to the UCSF Radiopharmaceutical Facility illustrates how facility control and environmental monitoring can affect product quality. The planning lesson is not to reproduce pharmaceutical inspection. It is to recognise that classified and quality-controlled spaces are not optional decorations that can be compressed whenever floor area becomes tight.
8. The facility contains several different clean/controlled environments
The cyclotron vault, radiochemistry space, aseptic area, quality-control laboratory, ordinary laboratory, waste area and office space do not have the same environmental requirements.
Mixing those categories into one “laboratory” use class can hide mechanical and spatial needs.
The site plan should distinguish where air systems, access control and maintenance regimes differ.
This also helps later adaptation, because adding a new product line may require a new controlled environment rather than just new benches.
9. Shielding changes building mass and structure
Radiation shielding can influence wall thickness, structural loading, equipment access and building geometry.
The precise design belongs to qualified specialists.
For planning, the important point is that an accelerator or hot-cell facility may not fit easily into a speculative office or light-laboratory shell.
A conversion that looks simple on a leasing plan can become structurally or spatially difficult once shielding, penetrations, service routes and maintenance access are included.
10. Equipment replacement needs a route through the building
Accelerators, shielded cells and associated plant have long service lives but are not permanent.
Large components may eventually need replacement.
The master plan should preserve a credible route for installation and removal without requiring demolition of unrelated occupied areas.
Heavy-equipment access, removable panels, loading zones and crane positions may therefore be part of the long-term land-use strategy.
11. The cyclotron is only one part of the production chain
Public attention often focuses on the accelerator because it is the most distinctive machine.
Operationally, production also depends on target handling, transfer systems, radiochemistry modules, hot cells, quality control, utilities, IT systems, trained staff, maintenance and logistics.
A region that buys or approves a cyclotron without building the rest of the chain has acquired a machine, not a reliable service.
Town planning should test the whole campus rather than one headline asset.
12. Hot cells need service space around the visible shielded box
A hot cell is not just a piece of furniture.
It can require ventilation interfaces, utilities, transfer routes, maintenance access and space for associated equipment.
When design teams compress service zones to maximise lettable or laboratory area, later maintenance can become awkward.
A facility that is hard to maintain is less resilient than one with deliberate service geography.
13. Aseptic fill and finishing can become the throughput constraint
Some facilities can produce radionuclide activity faster than they can formulate, fill, test and release final products.
This means the limiting space may not be the accelerator hall.
Planning should ask where material queues if one downstream step slows and whether the facility has enough controlled staging capacity to remain orderly.
Bottlenecks should be mapped by time, not only by floor area.
14. Quality-control laboratories are part of production, not an office support function
A batch cannot become useful merely because it has been produced.
It may require identity, purity, sterility-related, chemical, radiochemical or other tests depending on the product and jurisdiction.
The facility therefore needs laboratory capacity aligned with production volume and product diversity.
If quality-control capacity is undersized, the campus can have idle production equipment while batches wait for release.
15. The laboratory schedule is unusually compressed
For short-lived products, some quality activities happen under severe time pressure.
This can influence staffing, equipment redundancy and the location of laboratories relative to production.
The land-use lesson is that “nearby” can have operational value inside the campus.
A site split across distant buildings may create avoidable transfer time and security complexity.
16. Separate development work from routine clinical production
Research and development can involve changing methods, new equipment and experimental schedules.
Routine clinical production needs stable, validated operations.
Both can coexist on a campus, but the layout should make their relationship deliberate.
A research project should not casually consume space, utilities or access needed by a clinical production line that serves patients every morning.
17. Future isotopes may require different infrastructure
Medical-isotope demand is changing.
OECD Nuclear Energy Agency workshops in April and July 2026 highlighted growing interest in therapeutic radionuclides and the need for resilient supply chains, infrastructure, transport, waste management and workforce.
A campus designed only around today’s product can become obsolete if new production routes require different shielded spaces, chemistry, logistics or quality systems.
The master plan should therefore preserve adaptable laboratory and utility zones.
18. Do not assume one accelerator technology fits every future service
Different radionuclides can depend on different production technologies and supply routes.
Some are reactor-produced, some accelerator-produced, and some arrive from parent-generator systems or specialised suppliers.
Town planning should not prescribe the production physics.
It should require the operator to state the intended technology and keep future options realistic rather than promising an undefined ability to “make any isotope.”
19. Site selection should start with the healthcare network
Map the hospitals, nuclear-medicine departments and major patient centres that the facility expects to serve.
Then map travel time under real traffic conditions, not free-flow assumptions.
A central parcel may be geographically close but operationally slow if dispatch vehicles must cross congested urban roads.
A peripheral site with direct motorway access may perform better for regional distribution.
20. But distance from hospitals is not the only variable
A production site also needs suitable zoning, secure access, utilities, trained staff and a regulatory environment.
Placing the facility inside a hospital campus can simplify some clinical relationships but complicate construction, deliveries, expansion and emergency logistics.
There is no universal best location.
The correct location is where the full operating system works.
21. Airport access matters for some supply chains
Some medical isotopes or radiopharmaceuticals travel by air.
Airport access can therefore extend a facility’s service area and provide contingency options.
But airport proximity should be evaluated through cargo acceptance, operating hours, dangerous-goods rules, security, customs and ground-transport reliability.
A line on a map from the facility to the terminal does not prove a workable supply chain.
22. Road reliability matters every day
For local and regional deliveries, road transport can be the daily clock.
The route should be assessed for congestion, incident exposure, flood risk, planned works and alternate paths.
A facility serving time-sensitive products should know how much schedule margin exists under ordinary disruption.
Transport resilience can be more valuable than the shortest route.
23. Dispatch needs a dedicated operating edge
Patient-ready products should not compete with construction trucks, general waste collection or visitor traffic at one congested gate.
The dispatch area should support secure, controlled handoff and rapid departure.
Where multiple daily runs occur, queuing and vehicle circulation should remain inside the site.
The road outside should not become the facility’s waiting room.
24. Receiving and dispatch are different functions
Incoming targets, consumables, sterile components, laboratory supplies and maintenance parts have different timing and security needs from outgoing patient products.
A compact site may combine doors, but the operating logic should remain clear.
The layout should prevent an urgent medical dispatch from being trapped behind a routine delivery.
That is a small spatial decision with outsized reliability value.
25. Decay storage is time converted into space
Some radioactive material can be held until activity decreases sufficiently for the next lawful management step.
This means time itself creates a storage requirement.
The correct storage area depends on the materials, jurisdiction and approved waste route; town planning should not set technical holding periods.
The spatial lesson is that waste cannot always leave immediately, so secure and appropriately designed storage must be planned rather than improvised.
26. Waste categories should remain distinct
A radiopharmaceutical campus can generate ordinary municipal waste, pharmaceutical waste, chemical waste, radioactive material, sharps and laboratory waste.
Some items can fall into more than one regulatory category.
The planning submission should show how these streams remain identifiable and where each waits for its authorised route.
TPW-0277 remains the healthcare-waste treatment owner. This campus article only ensures that the source facility has enough space and access for lawful segregation and handoff.
27. Liquid waste needs a defined route
Some processes may generate liquid radioactive or chemically regulated streams.
Their management is highly jurisdiction-specific.
The land-use question is whether collection, storage, monitoring and authorised discharge or removal infrastructure physically fits the facility.
Do not allow a design to depend on “waste handled off site” without showing how waste reaches that off-site system.
28. Ventilation systems can be mission-critical infrastructure
Controlled radioactive work and aseptic pharmaceutical areas can impose demanding air-system requirements.
The planner does not set filtration specifications.
The planner should recognise that air-handling plant, exhaust routes, monitoring interfaces and maintenance access consume real roof and service-yard space.
Future roof loading and plant replacement should be considered before architectural features occupy every available zone.
29. Mechanical redundancy can be a healthcare resilience issue
A failed cooling or ventilation component can affect production even when the accelerator itself is healthy.
Critical mechanical systems should therefore be treated as part of production continuity.
The planning authority can ask whether the building provides space for required redundancy and maintenance isolation.
It should not attempt to decide the engineering standard.
30. Electrical reliability should be linked to the critical process list
Not every load requires the same continuity.
Production, environmental control, monitoring, security, IT, refrigerators or freezers and other systems may have different backup requirements.
A generic statement that the site has an emergency generator is not enough to understand resilience.
The project should maintain a critical-load strategy that is reviewed by the relevant technical authorities and reflected in the site layout.
31. Backup systems need physical space and lawful fuel or energy arrangements
Generators, batteries, fuel tanks or other resilience equipment can create noise, fire, access and maintenance considerations.
They should appear on the planning drawings early.
A common mistake is to reserve every attractive perimeter for landscaping and then insert emergency plant beside the nearest neighbour late in design.
Resilience equipment should be planned, not hidden.
32. Water needs are diverse
Radiopharmaceutical production can require potable water, purified water, cleaning water, cooling water and sanitary services.
The total volume may be modest compared with heavy industry, but quality and reliability can still matter.
The project should show a water balance appropriate to the process.
Where water scarcity is material, reuse opportunities should be assessed without compromising regulated product requirements.
33. Drainage design should distinguish clean and controlled areas
Stormwater from roofs and ordinary hardstanding should not be assumed to have the same risk profile as runoff from service or loading areas.
Spill-control and drainage arrangements should reflect the actual materials handled.
Critical plant should also be protected from relevant flood pathways.
A flood that never reaches the production room can still stop production if it disables a substation, access road or dispatch bay.
34. Flood resilience should use the patient service consequence
A generic industrial facility may be able to close for a day.
A sole-source medical-isotope facility may have broader consequences.
That does not justify building anywhere regardless of flood risk. It means the resilience analysis should consider the healthcare service that depends on the site.
Where the hazard is significant, relocation, elevation, protection or redundant supply should be compared transparently.
35. Seismic and structural resilience may matter disproportionately
Regions exposed to earthquake risk should consider both building safety and equipment continuity.
Shielded structures, precision equipment and utility systems can be difficult to restore quickly after damage.
The engineering belongs to specialists, but site selection can avoid unnecessary exposure.
A critical healthcare supply facility should not create avoidable regional fragility.
36. Security should be layered without destroying everyday functionality
Radioactive sources, pharmaceuticals and controlled materials require appropriate security.
The public realm does not need to become hostile as a result.
Setbacks, access control, vehicle management, screening and building layout can be integrated into a coherent campus.
A site that relies on ad hoc barriers and roadside inspection after opening will create operational and urban-design problems.
37. Cyber systems are part of physical continuity
Modern production equipment, quality systems, monitoring and logistics rely on digital systems.
Cybersecurity is governed by appropriate technical and organisational standards, not by zoning.
Yet the planning case should recognise physical dependencies such as diverse data links, secure server space, backup communications and protected network rooms where necessary.
A digital outage can become a production outage.
38. The workforce is unusually multidisciplinary
A radiopharmaceutical campus may need nuclear engineers or accelerator specialists, radiochemists, radiopharmacists, pharmacists, quality professionals, medical physicists, radiation-safety personnel, technicians, maintenance teams, validation specialists and logistics staff.
That labour pool is not evenly distributed.
A site far from research universities, hospitals and specialist training can face recruitment risk even if the land is cheap.
The workforce catchment should be mapped as seriously as the road catchment.
39. Training capacity belongs in the regional plan
Medical-isotope systems can expand faster than specialist labour supply.
The OECD-NEA’s 2026 Asia-Pacific work explicitly identified education, workforce development and capacity building as part of supply resilience.
Planning agencies do not run professional training, but economic-development promises should identify the institutions that can produce the required skills.
A facility without people is unused infrastructure.
40. A hospital partnership can reduce isolation
Production campuses often benefit from formal links with hospitals and research institutions.
These relationships can support clinical translation, workforce training, research and demand forecasting.
The spatial form varies: co-location, nearby districts or strong transport and institutional connections can all work.
The key is to avoid treating the plant as a detached industrial island if its success depends on constant interaction with healthcare.
41. Supplier geography can affect uptime
Critical maintenance parts, gases, sterile consumables, specialised containers and laboratory materials may have limited suppliers.
The facility should identify which inputs are locally available and which have long lead times.
This does not require every supplier to be on site.
It requires understanding where inventory, redundancy or regional supplier development is needed to prevent a small missing part from stopping production.
42. Quality failures need quarantine space
When a batch, material or component is under investigation, it should not be mixed back into normal flow.
Quarantine is therefore a physical function, not just a status in software.
The campus should have enough controlled space for abnormal material without blocking normal production.
This principle is reinforced by modern pharmaceutical quality systems: investigation capacity must exist before something goes wrong.
43. Product recalls and abnormal returns need a route
Although radiopharmaceutical logistics differ from ordinary medicines, the site should still have a plan for returned or rejected material where relevant.
That route should account for radioactive decay, pharmaceutical status and secure handling.
The planning concern is not the detailed procedure.
It is whether abnormal material can be received and contained without disrupting clean dispatch operations.
44. Expansion should protect the validated core
Adding a new laboratory or production line beside an operating regulated facility can create dust, vibration, utility interruptions and access conflicts.
A phased campus should separate construction movement from live production wherever practical.
Future expansion routes should be drawn before the first phase opens.
Otherwise, every later upgrade becomes a high-risk retrofit.
45. Construction phasing should include regulatory commissioning
A building is not operational merely because construction is complete.
Radiation systems, pharmaceutical spaces, utilities, monitoring and quality systems may require testing and regulatory approval.
The project programme should include that commissioning period.
Local authorities and investors should not promise a clinical-service date based only on structural completion.
46. Infrastructure headroom should be updated after each phase
Once a production line opens, the remaining electricity, cooling, water, laboratory and waste capacity should be recalculated.
Expansion plans often double-count spare capacity.
A live campus-capacity register prevents the same utility headroom from being promised to several future projects.
This is especially useful where the facility sits in a wider medical or research district.
47. Co-location with other laboratories can create shared opportunities
A science park may offer common security, waste contractors, emergency services, training and specialist maintenance.
Shared infrastructure can reduce duplication.
But shared systems can also create common-mode failure.
The campus should identify which services can safely be shared and which must remain independent because patient supply depends on them.
48. Neighbouring sensitive uses need a factual compatibility analysis
Public concern about radiation can be intense even when regulated exposure is low.
The response should be transparent evidence, not dismissal.
Explain which authority regulates radiological safety, what the planning authority controls, how transport and emergency arrangements work, and how the site interfaces with nearby uses.
Clear institutional boundaries build more trust than vague assurances that the facility is “safe.”
49. Emergency planning should be multi-agency
A radiopharmaceutical campus may need coordination among fire services, medical responders, radiation authorities, environmental regulators, police, utilities and site specialists.
The exact plan depends on the hazard assessment.
The town-planning contribution is to ensure access, assembly areas, service yards, hydrants or other required infrastructure are not obstructed by later development.
An emergency plan that cannot be executed on the physical site is only paperwork.
50. Community communication should use normal operations first
Public engagement often jumps directly to accident scenarios.
Begin by explaining what the facility does on an ordinary day: what comes in, what goes out, how often vehicles move, what regulators oversee different functions and what the product is used for.
Then explain abnormal situations proportionately.
People understand risk better when they first understand the system.
51. The campus can create a regional health-equity question
If advanced nuclear medicine depends on one urban production node, patients in distant or poorer regions may face weaker access.
Town planning cannot solve healthcare reimbursement or clinical allocation, but site strategy can consider the geographic reach of production and distribution.
A network of production, satellite radiopharmacies and clinical centres may offer different equity outcomes than one centralised site.
The appropriate model should be tested against population geography, not prestige.
52. Demand forecasting should separate diagnosis and therapy
Diagnostic and therapeutic isotope markets can behave differently.
A campus built for one established diagnostic product may not be the right platform for emerging radioligand therapies.
The OECD-NEA’s 2026 workshops emphasised that rapidly growing therapeutic demand changes production, waste, transport and healthcare-system requirements.
The business case should therefore show product-specific demand scenarios rather than one generic “nuclear medicine growth” curve.
53. Planning should test the downside demand case too
New therapies can grow quickly, but regulatory approvals, clinical adoption, reimbursement and competing technologies can change forecasts.
A campus designed only for the highest demand scenario risks overbuilding specialised space.
Flexible laboratories and phased production can reduce that risk.
Reserve option value without assuming every future product will scale.
54. Public investment should buy capability, not only equipment
Governments may fund accelerators as visible symbols of medical technology.
A resilient programme also needs workforce, maintenance, quality systems, distribution, replacement funding, waste routes and clinical demand.
The planning and funding case should therefore show lifecycle operating capability.
A machine without a durable operating ecosystem is a stranded asset.
55. The site-selection scorecard should compare time, regulation and resilience
A useful scorecard can include:
- travel time to major clinical demand;
- road and air-logistics reliability;
- suitable zoning and expansion space;
- regulatory pathway for radiation and pharmaceuticals;
- electrical and mechanical reliability;
- access to specialist labour;
- proximity to hospitals and research partners;
- space for controlled production, quality, waste and maintenance;
- flood, seismic and other natural-hazard exposure;
- security and emergency access;
- construction and commissioning complexity;
- alternate supply options if the site is unavailable.
Weightings should match the proposed service model.
The nearest site is not always the fastest system.
56. A constraint register should distinguish hard constraints from solvable ones
A weak electricity connection may be fixable with a funded upgrade.
A site inside an unacceptable hazard zone may not be.
A shortage of trained staff may be addressable over several years.
A road with no alternate path may remain a structural vulnerability.
By classifying constraints, planners and investors can spend effort on the problems that can actually be solved.
57. The approval should identify what is not authorised
“Radiopharmaceutical facility” can expand into new radionuclides, higher activity, new research or additional distribution.
The approval should clearly state the use envelope and the triggers for further review under relevant laws.
That protects both the operator and the community from ambiguity.
Flexible planning does not require undefined permission.
58. Monitoring should follow external effects and delivery promises
The planning authority should not duplicate radiation-dose monitoring or pharmaceutical-quality systems that belong to specialist regulators.
It may, however, monitor conditions such as traffic, noise, completion of mitigation, landscaping, drainage, access or agreed infrastructure.
A regulatory matrix can show who monitors what.
This prevents gaps and avoids several agencies collecting the same data for different reasons.
59. Closure planning should start before the first production run
A radiopharmaceutical site can contain specialised equipment, controlled areas and materials that require managed decommissioning.
The detailed decommissioning plan belongs to the competent radiation and environmental authorities.
Town planning should nevertheless consider the future land-use pathway: whether the building can be repurposed, what evidence is needed before another use enters and how long closure may take.
A specialised facility should not become an unexplained legacy site.
60. Worked example: central hospital site versus regional science-park site
Imagine a health system choosing between two locations.
Site A is inside a large hospital campus. It is close to clinicians and patients, has strong institutional relationships and could support research. But it has little expansion space, difficult construction access, congested roads and limited room for major mechanical plant.
Site B is in a regional science park fifteen kilometres away. It has excellent motorway access, a larger parcel, dedicated utilities and room for multiple production lines, but staff and clinicians must travel between institutions.
A superficial analysis chooses A because it is “closest to patients” or B because it is “industrial.”
A systems analysis measures production-to-administration time, delivery reliability, workforce travel, backup supply, construction phasing, utility resilience and future product growth.
The best answer may even be a network: production at B, satellite clinical preparation and research links at A, with validated logistics between them.
The point is not to prefer one urban form. It is to design the supply system deliberately.
61. Twelve questions before calling the campus implementation-ready
- What is produced on site and what arrives from elsewhere?
- Which products are diagnostic, therapeutic, research-only or future options?
- What production technology is proposed, and which regulator governs it?
- Where are controlled radiation areas, pharmaceutical areas, QC laboratories and ordinary support zones?
- What are the critical electricity, ventilation, cooling, water and IT dependencies?
- What happens if one critical utility or production element fails?
- How long does product take to reach each major clinical destination under normal and disrupted conditions?
- How are incoming materials, patient-ready dispatch, waste and construction traffic separated?
- Where do radioactive, pharmaceutical, chemical and ordinary wastes wait for their lawful route?
- Can the specialist workforce reach the site and can the region train replacements?
- What land and service routes are protected for future products or capacity?
- How will the site eventually be decommissioned or repurposed?
A campus that can answer these questions has moved beyond equipment procurement toward durable healthcare infrastructure.
62. Final principle: the product decays, so the city must coordinate
Medical-isotope planning exposes something fundamental about cities.
Some infrastructure cannot be understood as a building.
The useful product exists inside a chain of production, quality, regulation, transport, clinical demand, specialist labour and time. Break one link and the value created by the others can disappear quickly.
That is why the strongest radiopharmaceutical campus is not necessarily the one with the newest accelerator or the thickest walls.
It is the one whose physical geography allows a regulated medical product to move reliably from production to patient while preserving safety, quality, resilience and future capacity.
63. Implementation gate A: prove the service radius
Before land is committed, draw the actual clinical service area using realistic travel times.
Show the principal hospitals, alternate routes, likely dispatch windows and the maximum acceptable delay for the products in scope. Where air transport matters, include terminal handling and cut-off times rather than airport distance alone.
This converts “strategic location” from a marketing phrase into a measurable supply-chain proposition.
64. Implementation gate B: prove the regulatory stack
List the competent authorities for land use, building control, radiation protection, pharmaceutical manufacturing, environmental management, occupational safety, transport and emergency response.
For each, identify the approval or licence needed and the project stage at which it becomes critical.
A regulatory stack is not bureaucratic clutter. It is a dependency map. If one licence requires a design feature that another approval has not reserved space for, the problem should be discovered before construction.
65. Implementation gate C: prove patient-supply continuity
Identify the most credible outage scenarios: accelerator unavailability, utility failure, quality hold, transport disruption or loss of a key supplier.
Then show the alternate production or supply route.
The alternate may be another domestic facility, imported product, overlapping regional capacity or rescheduled clinical use depending on the healthcare system.
The planner need not validate medical decisions. The planner should understand whether the new campus reduces or concentrates regional fragility.
66. Implementation gate D: prove the abnormal-material space
On the difficult day, batches can be quarantined, returned material can arrive, waste can accumulate and a delivery can be delayed.
Show where that material goes without blocking normal circulation.
This is the difference between a facility designed for ideal production and one designed for regulated reality.
67. Implementation gate E: prove the maintenance geography
Map the service routes for accelerator systems, hot cells, air plant, electrical systems, laboratory equipment and backup infrastructure.
Confirm that technicians can reach the equipment without crossing controlled pharmaceutical zones unnecessarily and that major components can be replaced.
Maintenance access is rarely glamorous, but it is one of the strongest predictors of whether a specialised facility can remain reliable for decades.
68. Implementation gate F: prove the next product can be added without breaking the first
A growing radiopharmaceutical programme may add a new isotope, chemistry suite, QC method or distribution route.
Reserve flexible controlled space, utility capacity and regulatory separation where justified.
The aim is not to build speculative shielded rooms everywhere. It is to avoid a master plan in which every future innovation requires disrupting the operating clinical line.
69. Implementation gate G: record the boundaries of planning competence
The decision record should explicitly state which safety and quality matters are controlled by specialist regulators and which external land-use effects are controlled by planning.
This is good governance.
It prevents future planning staff from assuming that a planning approval replaced radiation licensing, and it prevents applicants from implying that specialist approval automatically resolves traffic, noise, flood or neighbourhood compatibility.
70. Implementation gate H: preserve institutional memory
A critical health facility may operate for decades while planners, regulators, hospital managers and operators change.
Keep a durable record of why the site was chosen, which corridors were protected, which expansion assumptions were used, which alternate routes were considered and which constraints were accepted.
Institutional memory is a form of infrastructure. It helps the next generation understand the physical logic they inherit.
71. Financing should distinguish capital cost from continuity cost
A cyclotron, shielded building and radiochemistry suite can be expensive, but the visible capital project is not the whole economic system.
Long-term costs include specialist maintenance, calibration, replacement parts, quality systems, training, regulatory compliance, secure transport, waste management and periodic upgrades. A funding model that can afford the launch but not the operating discipline may create an impressive facility with declining reliability.
For public projects, lifecycle funding should therefore be tested before land is committed. For private projects, the planning authority does not audit the business plan, but it can ask whether infrastructure promises depend on unfunded public upgrades.
72. The district needs a compatible emergency-service capability
A specialised facility should not be located on the assumption that ordinary emergency response automatically covers every scenario.
The operator and competent authorities should determine what specialist advice, equipment, training or access is needed. Where a regional hazardous-materials or radiological response team exists, travel time and access should be understood.
Town planning adds the physical layer: roads must support responders, gates must admit them, hydrants and assembly areas must remain usable, and later development must not obstruct the approved emergency plan.
73. Transport of radioactive material is a regulated system, not an informal courier job
Medical radioisotopes often travel in regulated packages under transport rules that sit outside ordinary parcel logistics.
The planning submission should identify the mode, frequency and route assumptions without attempting to rewrite those transport regulations.
The land-use implication is practical: secure loading, short internal travel, no uncontrolled public queuing and reliable access to the road or air network. If a project depends on a carrier or airport that cannot accept the relevant consignments at the required time, the location case is incomplete.
74. A science-park address does not automatically create compatibility
Science parks often mix laboratories, offices, teaching, start-ups, public events and sometimes housing or hospitality.
A radiopharmaceutical facility can fit within such a district, but only if the service edge, controlled areas, emergency access and logistics remain compatible with that mixed context.
Do not let the prestige of a “life-sciences” label substitute for a site-specific review. A small controlled-production facility can coexist well with research neighbours; a growing regional distribution campus may need a more robust industrial edge.
75. A hospital address does not automatically create operational suitability
Hospitals are complex, crowded estates with ambulances, patients, visitors, sterile departments, construction projects and limited service access.
Co-location can reduce clinical distance but increase competition for electrical capacity, plant rooms, loading docks and future land.
The estate master plan should compare the radiopharmaceutical project with other foreseeable hospital needs. A critical production function should not be placed where the next ward extension or utility upgrade will force it to move.
76. Regional networks can outperform a single “national flagship”
A government may prefer one flagship production centre for reasons of expertise and capital efficiency.
That can be sensible, but concentration also creates outage and transport risk.
A network can combine one major production hub with smaller cyclotron centres, radiopharmacies, generators, imported supply and clinical preparation sites. The right balance depends on population density, geography, product mix and healthcare organisation.
Town planning should make network alternatives visible before a single-site decision becomes irreversible.
77. Demand should be mapped by treatment pathway, not population alone
Two regions with the same population can have very different nuclear-medicine demand because clinical capacity, referral patterns, cancer centres, reimbursement, equipment and specialist staffing differ.
The facility business case should therefore map actual and planned PET/SPECT activity, radioligand-therapy capacity and referral networks where those data are available.
This also prevents a circular assumption in which the production plant is justified by future clinical demand that itself depends on the plant being built.
78. Product diversity can improve resilience while increasing complexity
A campus able to produce or prepare several products may make better use of equipment and staff and reduce dependence on one market.
But each additional product can add raw materials, analytical methods, controlled storage, quality documentation and waste routes.
The master plan should therefore treat portfolio growth as an infrastructure decision. A new product is not only a commercial line on a spreadsheet; it can create new spatial interfaces.
79. Public communication should explain benefits without promising individual access
A regional facility may improve availability of diagnostic imaging or therapy, support research and reduce dependence on distant supply.
Those are legitimate public benefits.
But planning documents should avoid implying that construction automatically guarantees affordable treatment, clinical eligibility or equal access. Those outcomes depend on healthcare policy and medical decisions outside land-use planning.
Clear boundaries make the public-value case more credible.
80. The final site should preserve optionality without creating unnecessary exclusion
Radiopharmaceutical production requires controlled areas, but not every metre around the campus needs to be sterilised of other urban uses.
Use the actual hazard, service and expansion requirements to determine the appropriate edge.
Over-buffering can waste scarce urban land and isolate workers; under-buffering can constrain the facility and create conflict. The best boundary is evidence-based, reviewable and tied to the real operating envelope.
Evidence base and current planning signals
This article was prepared against current high-authority material available in September 2026:
- OECD Nuclear Energy Agency, Third International Workshop on Medical Radioisotopes Supply (9–10 April 2026), which highlights rapid growth in therapeutic radioisotope demand, supply-chain resilience, infrastructure, waste, transport and policy: https://www.oecd-nea.org/jcms/pl_113668/third-international-workshop-on-medical-radioisotopes-supply
- OECD Nuclear Energy Agency and ANSTO, Asia-Pacific Workshop on Medical Radioisotopes (6–7 July 2026), covering production, processing, transport, regulatory approval, end use, infrastructure and workforce: https://oecd-nea.org/jcms/pl_117868/asia-pacific-workshop-on-medical-radioisotopes
- OECD Nuclear Energy Agency, First Asia-Pacific medical radioisotopes workshop strengthens regional collaboration (15 July 2026): https://oecd-nea.org/jcms/pl_120329/first-asia-pacific-medical-radioisotopes-workshop-strengthens-regional-collaboration
- International Atomic Energy Agency, Cyclotrons used for Radionuclide Production, maintained in response to worldwide interest in medical-radioisotope cyclotron installation and use: https://nucleus.iaea.org/sites/accelerators/Pages/Cyclotron.aspx
- International Atomic Energy Agency, Nuclear Medicine Database, describing the global infrastructure and workforce components of nuclear-medicine practice: https://nucleus.iaea.org/Pages/nuclear-medicine-db.aspx
- U.S. Food and Drug Administration, UCSF Radiopharmaceutical Facility warning letter (13 April 2026), showing the operational importance of facilities, environmental control, investigations and quality oversight for short-expiry sterile products: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ucsf-radiopharmaceutical-facility-719568-04132026
- American Planning Association, APA Foresight / 2026 Trend Report for Planners, for the wider planning duty to prepare for emerging technological and health-infrastructure change: https://www.planning.org/foresight/
- UN-Habitat, Agenda to Action: Implementation of the New Urban Agenda in Nine Cities Across the Globe (2026), for multilevel coordination, evidence-based decision-making and implementation systems: https://unhabitat.org/agenda-to-action-implementation-of-the-new-urban-agenda-in-nine-cities-across-the-globe
- World Bank, Cities that Work: Realizing the Jobs Potential of MENA’s Cities launch material (30 June 2026), for the importance of aligning land use, reliable infrastructure, labour access and productive investment: https://www.worldbank.org/en/news/press-release/2026/06/25/mena-cities-can-become-powerful-engines-of-jobs-and-growth
Search-demand note: current Ahrefs Keywords Explorer metrics were requested during topic selection, but the connected account returned Insufficient plan. No search-volume or keyword-difficulty numbers have been invented. Demand is instead supported by current OECD-NEA workshops explicitly reporting expanding therapeutic-isotope demand and supply-chain needs, the IAEA’s active global cyclotron infrastructure resources, current regulatory attention and the verified absence of a dedicated eduKateSG Town Planning owner for this reader job.